Graph takes few seconds to load...
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance.
The company’s lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib.
It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
| Annual Data | Millions of US $ except per share data | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|
| Cash on hand | $383.93 | $114.59 | $16.40 | $36.92 |
| Receivables | - | - | - | - |
| Inventory | - | - | - | - |
| Pre-Paid Expenses | - | - | - | - |
| Other Current Assets | - | - | $1.32 | $0.52 |
| Total Current Assets | $386.99 | $117.30 | $17.72 | $37.44 |
| Property, Plant, And Equipment | $11.72 | $1.21 | $1.12 | $1.03 |
| Long-Term Investments | - | - | - | - |
| Goodwill And Intangible Assets | - | - | - | - |
| Other Long-Term Assets | $0.43 | $0.43 | $0.26 | $0.24 |
| Total Long-Term Assets | $12.14 | $1.64 | $1.38 | $1.27 |
| Total Assets | $399.13 | $118.94 | $19.10 | $38.70 |
| Total Current Liabilities | $22.76 | $14.66 | $11.13 | $12.05 |
| Long Term Debt | $29.64 | - | $0.25 | $4.10 |
| Other Non-Current Liabilities | $0.39 | $0.12 | $0.32 | $0.26 |
| Total Long Term Liabilities | $38.79 | $0.12 | $0.58 | $9.33 |
| Total Liabilities | $61.55 | $14.78 | $11.71 | $21.38 |
| Common Stock Net | $0400000 | $0300000 | $0100000 | $0100000 |
| Retained Earnings (Accumulated Deficit) | $-319.39 | $-233.84 | $-173.91 | $-138.54 |
| Comprehensive Income | - | - | - | - |
| Other Share Holders Equity | $-0600000 | - | - | - |
| Share Holder Equity | $337.58 | $104.16 | $7.40 | $17.33 |
| Total Liabilities And Share Holders Equity | - | - | - | - |
